Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks-Reference-Cited by-同舟云学术

Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks

Published:2019-07-18 Issue:3 Volume:182 Page:605-617
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Reich K.¹²,Warren R.B.³,Iversen L.⁴^ORCID,Puig L.⁵,Pau‐Charles I.⁶,Igarashi A.⁷,Ohtsuki M.⁸,Falqués M.⁶,Harmut M.⁶,Rozzo S.⁹,Lebwohl M.G.¹⁰,Cantrell W.¹¹,Blauvelt A.¹²^ORCID,Thaçi D.¹³

Affiliation:

1. Centre for Translational Research in Inflammatory Skin Diseases Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg‐Eppendorf Skinflammation^® Center Hamburg Germany

2. Dermatologikum Berlin Berlin Germany

3. Dermatology Centre Salford Royal NHS Foundation Trust Manchester NIHR Biomedical Research Centre The University of Manchester Manchester U.K.

4. Department of Dermatology Aarhus University Hospital Aarhus Denmark

5. Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona Barcelona Spain

6. Almirall R&D Barcelona Spain

7. NTT Medical Center Tokyo Tokyo Japan

8. Department of Dermatology Jichi Medical University Tochigi Japan

9. Sun Pharmaceuticals Princeton NJ U.S.A.

10. Icahn School of Medicine at Mount Sinai New York NY U.S.A.

11. Department of Dermatology University of Alabama at Birmingham Birmingham AL U.S.A.

12. Oregon Medical Research Center Portland OR U.S.A.

13. Institute and Comprehensive Centre for Inflammation Medicine University of Lübeck Lübeck Germany